title: Reducing the burden of depression in youth: what are the implications of neuroscience and genetics on policies and programs?
abstract: Mood disorders are a leading cause of the burden of disease in youth. Three critical lessons emerge from the reviews in this issue that are relevant to our understanding of these common mental disorders: first, that the brain is in a highly dynamic stage of its development during youth; second, that environmental factors interact with genetic factors to influence the probability of risk behaviors and dysphoric states; and third, that shared developmental and genetic factors may account for the bulk of emotional and behavioral outcomes in youth, and that environmental influences may affect the specific expression of the phenotypes associated with these pathways. Although this evidence does not immediately indicate the potential for new interventions, it is consistent with current policy and practice recommendations. Interventions should focus on both improving the early detection and management of depressive disorders as well as preventive strategies that aim to train children and youth to improve cognitive control and manage stress more effectively. Limiting access to harmful risk-taking situations and providing opportunities to engage are less harmful, but equally exciting, alternatives in a pragmatic universal prevention policy option. Key research priorities and paradigms emerge from this evidence, particularly in the context of the grand challenges in global mental health.
authors: London School of Hygiene and Tropical Medicine, London, UK. Electronic address: vikram.patel@lshtm.ac.uk.
authors: Vikram
authors: V
authors: Patel
mesh_terms: D000293:Adolescent; D000294:Adolescent Behavior / Q000502:physiology / Q000523:psychology; D041923:Adolescent Development / Q000502:physiology*; D001921:Brain / Q000254:growth & development*; D003866:Depressive Disorder / Q000235:genetics / Q000517:prevention & control* / Q000628:therapy; D003906:Developing Countries; D004777:Environment; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D010641:Phenotype; D011613:Psychotherapy / Q000379:methods / Q000592:standards; D012309:Risk-Taking; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
chemical_list: D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors